Gere S. P.
- Country
- Austria
- Department
- Medical University Vienna, Department of Medicine III, Division of Nephrology and Dialysis
Research Overview
- Evaluation of Setanaxib's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Alport Syndrome: A Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial
- Evaluation of Iptacopan (LNP023) Efficacy and Safety in Complement Inhibitor-Naïve Adult Patients with Atypical Hemolytic Uremic Syndrome
- Evaluation of Pegcetacoplan for Safety and Efficacy in Post-Transplant Recurrence of Complement 3 Glomerulopathy or Immune Complex Membranoproliferative Glomerulonephritis
Data & Insights
Has run more than one trial at 7 of 45 partner sites.
Specializations
Glomerular Diseases
This investigator specializes in treating complex glomerular disorders, with particular focus on complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN).
- C3G Management
- IC-MPGN Treatment
- Post-transplant Recurrence
Their research encompasses innovative therapeutic approaches for managing these rare kidney conditions.
Rare Genetic Disorders
The investigator conducts research in rare genetic conditions affecting kidney function, including Alport syndrome and Fabry disease.
- Genetic Kidney Disorders
- Novel Therapeutic Applications
- Long-term Disease Management
Their work focuses on evaluating new treatment options for these hereditary conditions.
Complement-Mediated Diseases
This investigator specializes in complement-mediated disorders, with particular expertise in atypical hemolytic uremic syndrome (aHUS) and related conditions.
- Complement Inhibitor Therapy
- Thrombotic Microangiopathy
- Novel Treatment Approaches
Their research explores innovative therapeutic strategies for complement-related disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.